东亚药业(605177.SH)：王胜辞去公司第四届董事会非独立董事、战略委员会委员的相关职务

Core Viewpoint - East Asia Pharmaceutical (605177.SH) announced the resignation of non-independent director Wang Sheng due to adjustments in the company's governance structure, effective immediately upon submission of his resignation report [1] Group 1: Resignation Details - Wang Sheng submitted a written resignation report to the company's board on December 25, 2025, resigning from his position as a non-independent director and a member of the strategic committee of the fourth board [1] - Despite his resignation from the board, Wang Sheng will continue to serve as the general manager of a subsidiary of the company [1] Group 2: Board Elections - On December 25, 2025, the company held a staff representative meeting to elect Wang Sheng as a staff representative director of the fourth board, with a term consistent with that of the fourth board [1]